Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
GlaxoSmithKline Consumer Holding B.V., commonly referred to as GSK Consumer Healthcare, is a leading player in the global consumer health industry, headquartered in the Netherlands (NL). Founded in 2000, the company has established a strong presence in major operational regions, including Europe, North America, and Asia.
GSK Consumer Healthcare focuses on delivering innovative over-the-counter products, oral health solutions, and wellness supplements, with a commitment to quality and efficacy that sets them apart in the market. Their portfolio includes well-known brands such as Sensodyne, Panadol, and Voltaren, which are recognised for their effectiveness and consumer trust.
With a robust market position, GSK Consumer Healthcare has achieved significant milestones, including advancements in product development and sustainability initiatives, reinforcing its reputation as a leader in consumer health.
+71 vs industry average
Glaxosmithkline Consumer Holding B.V.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Real Estate Services has above-average carbon intensity
The Real Estate Services industry has reduced its overall emissions by 17% since 2018
No reported emissions data is available for Glaxosmithkline Consumer Holding B.V. yet.
Glaxosmithkline Consumer Holding B.V., headquartered in the Netherlands (NL), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, which means that any climate commitments or emissions data may be inherited from its parent organisation.
GSK plc has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded to Glaxosmithkline Consumer Holding B.V. These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations. However, specific reduction targets or achievements for Glaxosmithkline Consumer Holding B.V. have not been detailed.
As part of its commitment to sustainability, GSK plc is actively working towards reducing its carbon footprint and enhancing its climate resilience, which may influence the operational strategies of Glaxosmithkline Consumer Holding B.V. in the future.
No climate goals have been disclosed for Glaxosmithkline Consumer Holding B.V. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Glaxosmithkline Consumer Holding B.V. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more